These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 19018722)

  • 21. Core myopathies and risk of malignant hyperthermia.
    Klingler W; Rueffert H; Lehmann-Horn F; Girard T; Hopkins PM
    Anesth Analg; 2009 Oct; 109(4):1167-73. PubMed ID: 19762745
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Functional characterization of malignant hyperthermia-associated RyR1 mutations in exon 44, using the human myotube model.
    Wehner M; Rueffert H; Koenig F; Olthoff D
    Neuromuscul Disord; 2004 Jul; 14(7):429-37. PubMed ID: 15210166
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evidence for a spontaneous C1840-T mutation in the RYR1 gene after DNA fingerprinting in a malignant hyperthermia susceptible family.
    Steinfath M; Seranski P; Singh S; Fiege M; Wappler F; Schulte Am Esch J; Scholz J
    Naunyn Schmiedebergs Arch Pharmacol; 2002 Oct; 366(4):372-5. PubMed ID: 12237752
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Identification of a novel mutation in the ryanodine receptor gene (RYR1) in a malignant hyperthermia Italian family.
    Fortunato G; Berruti R; Brancadoro V; Fattore M; Salvatore F; Carsana A
    Eur J Hum Genet; 2000 Feb; 8(2):149-52. PubMed ID: 10757649
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Several interacting genes influence the malignant hyperthermia phenotype.
    Robinson R; Hopkins P; Carsana A; Gilly H; Halsall J; Heytens L; Islander G; Jurkat-Rott K; Müller C; Shaw MA
    Hum Genet; 2003 Feb; 112(2):217-8. PubMed ID: 12522565
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Malignant hyperthermia].
    Metterlein T; Schuster F; Graf BM; Anetseder M
    Anaesthesist; 2014 Dec; 63(12):908-18. PubMed ID: 25384957
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Malignant hyperthermia and central core disease causative mutations in Swedish patients.
    Broman M; Islander G; Müller CR; Ranklev-Twetman E
    Acta Anaesthesiol Scand; 2007 Jan; 51(1):50-3. PubMed ID: 17081152
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dynamic alterations in myoplasmic Ca2+ in malignant hyperthermia and central core disease.
    Lyfenko AD; Goonasekera SA; Dirksen RT
    Biochem Biophys Res Commun; 2004 Oct; 322(4):1256-66. PubMed ID: 15336973
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Novel ryanodine receptor mutation that may cause malignant hyperthermia.
    Kaufmann A; Kraft B; Michalek-Sauberer A; Weigl LG
    Anesthesiology; 2008 Sep; 109(3):457-64. PubMed ID: 18719443
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Identification of malignant hyperthermia-susceptible ryanodine receptor type 1 gene (RYR1) mutations in a child who died in a car after exposure to a high environmental temperature.
    Nishio H; Sato T; Fukunishi S; Tamura A; Iwata M; Tsuboi K; Suzuki K
    Leg Med (Tokyo); 2009 May; 11(3):142-3. PubMed ID: 19223216
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [What significance to genotype changes have in diagnosis of malignant hyperthermia?].
    Steinfath M; Scholz J; Singh S; Wappler F
    Anasthesiol Intensivmed Notfallmed Schmerzther; 1996 Aug; 31(6):334-43. PubMed ID: 8962927
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Skeletal muscle ryanodine receptor mutations associated with malignant hyperthermia showed enhanced intensity and sensitivity to triggering drugs when expressed in human embryonic kidney cells.
    Sato K; Roesl C; Pollock N; Stowell KM
    Anesthesiology; 2013 Jul; 119(1):111-8. PubMed ID: 23459219
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Correlations between genotype and pharmacological, histological, functional, and clinical phenotypes in malignant hyperthermia susceptibility.
    Monnier N; Kozak-Ribbens G; Krivosic-Horber R; Nivoche Y; Qi D; Kraev N; Loke J; Sharma P; Tegazzin V; Figarella-Branger D; Roméro N; Mezin P; Bendahan D; Payen JF; Depret T; Maclennan DH; Lunardi J
    Hum Mutat; 2005 Nov; 26(5):413-25. PubMed ID: 16163667
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Molecular pathology of malignant hyperthermia and central core disease].
    Takagi A
    Nihon Rinsho; 1997 Dec; 55(12):3307-14. PubMed ID: 9436456
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Malignant hyperthermia.
    Rosenberg H; Davis M; James D; Pollock N; Stowell K
    Orphanet J Rare Dis; 2007 Apr; 2():21. PubMed ID: 17456235
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ryanodine receptor gene is a candidate for predisposition to malignant hyperthermia.
    MacLennan DH; Duff C; Zorzato F; Fujii J; Phillips M; Korneluk RG; Frodis W; Britt BA; Worton RG
    Nature; 1990 Feb; 343(6258):559-61. PubMed ID: 1967823
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Increased sensitivity of the ryanodine receptor to halothane-induced oligomerization in malignant hyperthermia-susceptible human skeletal muscle.
    Glover L; Heffron JJ; Ohlendieck K
    J Appl Physiol (1985); 2004 Jan; 96(1):11-8. PubMed ID: 12959958
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Malignant hyperthermia].
    Glahn KP
    Ugeskr Laeger; 2003 Apr; 165(17):1763-8. PubMed ID: 12768904
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mutated p.4894 RyR1 function related to malignant hyperthermia and congenital neuromuscular disease with uniform type 1 fiber (CNMDU1).
    Haraki T; Yasuda T; Mukaida K; Migita T; Hamada H; Kawamoto M
    Anesth Analg; 2011 Dec; 113(6):1461-7. PubMed ID: 21926372
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A case of discordance between genotype and phenotype in a malignant hyperthermia family.
    Fortunato G; Carsana A; Tinto N; Brancadoro V; Canfora G; Salvatore F
    Eur J Hum Genet; 1999; 7(4):415-20. PubMed ID: 10352931
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.